tbuckley/cabot-search huggingface dataset:
Magnetic Resonance Imaging
Authors: None Herbert L.
Journal: JAMA (1988)

Magnetic resonance imaging (MRI) is a new and innovative technique that affords anatomic images in multiple planes and that may provide information about tissue characterization. The first magnetic resonance image was published in 1973 by Paul Lauterbur, PhD. Since that time, major technological advances, together with increasing clinical and investigative interests in the method, have been accompanied by the development of equipment that is now clinically applicable to man, with potentially great benefits in assessing pathophysiological states. The magnetic resonance images are obtained by placing the patient or the area of interest within a powerful, highly uniform, static magnetic field. Magnetized protons (hydrogen nuclei) within the patient align like small magnets in this field. Radiofrequency pulses are then used to create an oscillating magnetic field perpendicular to the main field from which the nuclei absorb energy and move out of alignment with the static field in a state of excitation.
The Commission Evil.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LETTER FROM NEW YORK.
Authors: None P. B. P.
Journal: JAMA (1890)

(FROM OUR OWN CORRESPONDENT.) <i>New York County Medical Association—The Immateriality of Life and of Disease—A Case of Extra-uterine Pregnancy— The Saturday and Sunday Hospital Collections</i>. The March Meeting of the New York County Medical Association was one of the largest in the history of the Association. Dr. James R. Leaming, the well-known authority on diseases of the chest, read a philosophical paper on "The Immateriality of Life and of Disease," in which he expressed views on pathology considerably at variance with those commonly accepted at the present day, and somewhat startled his hearers by his skepticism as to the causative agency of morbific microbes. In speaking of phthisis he stated that in his opinion the bacilli found to be present simply fed on the dead atoms found in the tissues like mold on decaying matter, and that he did not believe they were the cause, but the consequence of the
Society of Uroradiology—Annual Postgraduate Course
Journal: JNCI Journal of the National Cancer Institute (1987)

Society of Uroradiology—Annual Postgraduate Course Get access JNCI: Journal of the National Cancer Institute, Volume 79, Issue 4, October 1987, Page 909, https://doi.org/10.1093/jnci/79.4.909-b Published: 01 October 1987
Open-label phase II study evaluating the efficacy of concurrent administration of radium Ra 223 dichloride and abiraterone acetate in men with castration-resistant prostate cancer patients with symptomatic bone metastases.
Authors: Luke T. Nordquist, Neal D. Shore
Journal: Journal of Clinical Oncology (2016)

e16546 Background: This study evaluates the prospective combinatorial use of Ra-223 + AA in CRPC patients with symptomatic bone metastases in both the pre- and post-chemotherapy setting. Radium Ra 223 dichloride (Ra-223), an intravenous alpha-emitting radioisotope, is a calcium mimetic, forming complexes with hydroxyapatite at sites of bone metastasis for CRPC patients. Abiraterone Acetate (AA), an oral androgen biosynthesis inhibitor, decreases serum testosterone for patients with CRPC. Methods: This open-label, phase 2 study (NCT02097303), evaluated CRPC patients with symptomatic bone disease. Patients received Rad-223 Q 4 weeks x 6 and concomitant AA 1000 mg + prednisone 5 mg BID. Primary endpoints were quality of life (QOL) and pain responses. Secondary endpoints included safety, disease progression, SRE's, PSA and ALP response, progression to further antineoplastic therapy and performance status (ECOG) changes. Patients were assessed at Screening, six 4-week intervals and End of Treatment (EOT). Results: 31 subjects received all 6 cycles of Rad-223 with concurrent AA. From the Screening visit through the EOT visit subjects reported an overall 30% decrease in bone pain, a 47% decrease in the amount of bone pain that interfered with their general activity, and a 13% decrease in use of non-narcotic pain medications. Significant increases in QOL measurements and a stability of ECOG scores were noted, as well as a paucity of clinically significant abnormal serological parameters. Bone scan results demonstrated a 76% decrease in the number of subjects who showed progressive disease and a 30% increase in the number of subjects that showed stable disease. CT scan results demostrated that 8 subjects who were progressing at Screening were either stable or improving at EOT. No SRE's or progression to antineoplastic occured during the study. Conclusions: To our knowledge, this is the largest prospective trial to date of Rad-223 and AA, which demonstrated not only an improvement in QOL assessments but also confirmed the safety and tolerability of this synergistic strategy of FDA approved CRPC agents. Clinical trial information: NCT02097303.
THE LESSENED BIRTH RATE.
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PRACTICAL EXAMINATIONS FOR LICENSURE.
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatments of homosexuality in Britain since the 1950s—an oral history: the experience of professionals
Authors: Michael King, Glenn Smith, Annie Bartlett
Journal: BMJ (2004)

<h3>Abstract</h3> <b>Objective</b> To investigate the experiences of professionals who administered and evaluated treatments for homosexuality in Britain since the 1950s. <b>Design</b> A nationwide study based on qualitative interviews. <b>Participants</b> 30 health professionals who developed and practised treatments for homosexuality. <b>Results</b> A range of treatments were developed to make homosexuals into heterosexuals, the most common of which were behavioural interventions. Treatments were based on little evidence of effectiveness and were open to the criticism that legal or social pressures coerced patients. Treatments did not become mainstream within British mental health services. With hindsight, professionals realised that they had not appreciated the influence of social context on sexual behaviour. Most now regarded same sex attraction as compatible with psychological health, although a small minority considered that the option to try to become heterosexual should still be available to patients who desire it. <b>Conclusions</b> Social and political assumptions sometimes lie at the heart of what we regard as mental pathology and serve as a warning for future practice.
Diabetic ketoacidosis
Authors: R. Bienia
Journal: JAMA (1979)

IN RECENT years there has been a great deal of controversy over optimal insulin therapy for diabetic ketoacidosis. The disputes have centered on the issues of traditional high-dose vs low-dose insulin regimens and intravenous (IV) vs intramuscular (IM) administration.<sup>1-4</sup>The results with any of the accepted regimens are acceptable, implying that the physician should use the protocol with which he is both familiar and comfortable. <h3>Pathophysiology</h3> The hallmark of diabetic ketoacidosis is a relative insulin deficit. This results in hyperglycemia with glycosuria once the renal threshold for glucose is exceeded. The resulting osmotic diuresis leads to dehydration, which is intensified if the patient vomits. In the absence of adequate insulin, the body is unable to use glucose as an energy source and must turn to long-chain fatty acids that are mobilized from adipose stores. The end products of this metabolism are β-hydroxybutyric acid and acetoacetic acid, generally in a
Measuring and Knowing
Authors: John T. Gwynne
Journal: JAMA (1991)

The evidence that lowering serum low-density lipoprotein (LDL) cholesterol levels prevents both primary and recurrent myocardial infarction now seems overwhelming. Two major primary prospective intervention trials, the Lipid Research Primary Prevention Trial<sup>1,2</sup>and the Helsinki Heart Study,<sup>3,4</sup>have shown that lowering total and LDL cholesterol levels will decrease the incidence of fatal and nonfatal myocardial infarctions in high-risk middle age men. The outcome of these trials is quantitatively consistent with less-definitive primary prevention trials employing diet alone and is consistent with the degree of benefit predicted by observational epidemiologic studies relating total cholesterol to coronary artery disease risk.<sup>2,5</sup>Treatment with nicotinic acid as part of the Coronary Drug Project, a secondary prevention trial in middle-aged men, not only decreased the incidence of nonfatal reinfarction<sup>6</sup>but also appeared to have decreased mortality at the 15-year follow-up.<sup>7</sup>The results of recent pharmacologic
Folylpolyglutamyl Synthetase Gene Transfer and Glioma Antifolate Sensitivity in Culture and In Vivo
Authors: M. Aghi, C. M. Kramm, X. O. Breakefield
Journal: JNCI Journal of the National Cancer Institute (1999)

BACKGROUND: Although antifolates are popular agents for use in chemotherapy, they display minimal toxicity against slow-growing tumors and are toxic to actively replicating cells in normal tissues. These drugs are converted intracellularly into polyglutamate derivatives by the enzyme folylpolyglutamyl synthetase (FPGS). Because tumors with high expression of FPGS often respond to nontoxic antifolate doses, we investigated whether augmenting tumoral FPGS activity by gene delivery would enhance tumoral antifolate sensitivity. METHODS: 9L rat gliosarcoma cells were stably transfected with a human FPGS complementary DNA (cDNA), producing 9L/FPGS cells. The sensitivity of these cells to the antifolates methotrexate and edatrexate was measured in culture and in subcutaneous tumors, as was their ability to increase the chemosensitivity of nearby nontransfected cells, i.e., a bystander effect. The antifolate sensitivity of nonselected cells transduced with a hybrid amplicon vector that expressed FPGS was also ascertained. RESULTS: In comparison with 9L cells, 9L/FPGS cells displayed enhanced sensitivity to 4-hour pulses of antifolate. Subcutaneous 9L/FPGS tumors responded as well to methotrexate given every third day as 9L tumors did to daily treatment. A modest bystander effect was observed with edatrexate treatment in culture and in vivo . The observed bystander effect appeared to result from the release of antifolates by transfected cells after the removal of extracellular drug. In culture, enhanced antifolate sensitivity was also seen in other stably transfected rodent and human glioma cell lines, including one with high pre-existing FPGS activity, and in canine and human glioblastoma cell lines transduced with a vector bearing FPGS cDNA. CONCLUSIONS: FPGS gene delivery enhances the antifolate sensitivity of several glioma cell lines and merits further evaluation as a therapeutic strategy.
Incidence of Color Vision Defects in Toronto Grade 6 School Children
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Study of the Ionization Method for Measuring the Intensity and Absorption of Roentgen Rays and of the Efficiency of Different Filters Used in Therapy
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue Access Provided by Korea University Medical Library JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account
Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Authors: Aryeh Shander
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Spanish Toxic Oil Syndrome 20 Years after Its Onset: A Multidisciplinary Review of Scientific Knowledge
Authors: Emilio Gelpí, Manuel Posada de la Paz, Benedetto Terracini, Ignacio Abaitua, Agustín Gómez de la Cámara, Edwin M. Kilbourne, Carlos Lahoz, Bénoit Nemery, Rossanne M. Philen, Luis Soldevilla, Stanislaw Tarkowski, CISAT Scientific Committee
Journal: Environmental Health Perspectives (2002)
Novel stratification of the recurrence risk following surgical extirpation of clear cell renal cell carcinoma using tissue biomarkers in the mammalian target of rapamycin pathway.
Authors: Oussama M. Darwish, Ganesh Raj, Ramy F. Youssef, Payal Kapur, Aditya Bagrodia, Michael Belsante, Yair Lotan, Vitaly Margulis
Journal: Journal of Clinical Oncology (2013)

372 Background: Aberrant activation of the mammalian target of rapamycin (mTOR) pathway promotes invasiveness and metastatic potential in a variety of malignancies. The aim of the present study was to evaluate the association of altered expression of mTOR pathway components with recurrence outcome in non-metastatic clear cell renal cell carcinoma (ccRCC) patients. Methods: Immunohistochemistry for phos-S6, phos-mTOR, mTOR, phos-AKT, HIF-1α, RAPTOR, PTEN, PI3K, and phos-4EBP1 was performed on tissue microarrays of patients treated for non-metastatic kidney cancer between 1997-2010. Patients were defined as having a low (&lt;) or high risk (≥) of nomogram predicted recurrence (2001 MSKCC RCC post-op) using an 8% cutoff. The relationship between individual marker expression, as well as combined marker score (low, intermediate and high defined as ≤ 3, 4-5, &gt;5 altered biomarkers; respectively) with the actual and predicted relapse rates was assessed. Results: The study included 419 non-metastatic ccRCC patients (pT1-T2 79.5%, pT3-T4 20.5%, Fuhrman nuclear grade 1-2 in 69%, 3-4 in 31%). 219 and 200 patients had low (&lt;8%) and high (≥8%) nomogram-predicted 5-year risk of recurrence respectively. With a median follow-up of 2.2 years, recurrences were detected in 5 (2.3%) of the predicted low risk and 30 (15%) of the predicted high risk patients. mTOR pathway biomarker profiles were not predictive for patients at low predicted risk of recurrences. For patients at high predicted risk of recurrence, low, intermediate and high combined marker scores were found in 84 (42%), 79 (39.5%), and 37 (18.5%), respectively. The actual rates of recurrence were noted for 8.3% of low, 13.9% of intermediate and 32.4% of high combined marker score in a statistically significant distribution (p=0.027). Conclusions: The cumulative number of aberrantly expressed mTOR biomarkers correlates with a higher rate of recurrence. The combined marker score may help further stratify patients with high nomogram predicted risk of recurrence. Our data supports prospective evaluation of these biomarkers to augment current clinico-pathologic predictors of outcomes in ccRCC.
Side Glance : Pseudopodia
Journal: JNCI Journal of the National Cancer Institute (1995)

Side Glance : Pseudopodia Get access JNCI: Journal of the National Cancer Institute, Volume 87, Issue 6, 15 March 1995, Page 409, https://doi.org/10.1093/jnci/87.6.409 Published: 15 March 1995
SHOULD CASES OF TUBERCULAR CONSUMPTION BE REPORTED TO LOCAL BOARDS OF HEALTH?
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Acta Orthopaedica Scandinavica, Copenhagen
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue Access Provided by Korea University Medical Library JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account